When Wall Street analysts decide to come out of their caves and boost a certain stock, retail investors should pay attention ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price target lifted by stock analysts at JPMorgan Chase & Co. from ...

Gilead Sciences Inc. CEO Daniel O'Day's compensation rose 4.8% last year to $23.7 million — roughly $97 for every buck made ...

Riyadh, October 12, 2022, SPA -- King Faisal Specialist Hospital & Research Center (KFSHRC) has signed a memorandum of understanding with Kite-Gilead ... high quality within an environment of an ...

This article is based on a press release statement from Gilead Sciences. While trading at a relatively high earnings multiple, InvestingPro data suggests the company maintains strong cash flows and ...

This article is based on a press release statement from Gilead Sciences. While trading at a relatively high earnings multiple, InvestingPro data suggests the company maintains strong cash flows ...

Gilead Sciences announced a significant milestone ... As the fight against HIV evolves, our high-quality antigens empower researchers, vaccine developers, and diagnostic innovators to stay ...

After Gilead Sciences' lenacapavir made waves with stellar ... according to Baeten. Gilead, riding high from HIV sales boost, charts course for long-acting PrEP launch In the phase 1 study ...

Gilead (GILD) Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company’s injectable HIV-1 capsid inhibitor ...

Analysts have recently evaluated Gilead Sciences and provided 12-month price targets. The average target is $115.29, accompanied by a high estimate of $140.00 and a low estimate of $84.00.